Pneumonia is the most frequent complication of COVID-19, due to an aberrant host immune response that is associated with an acute respiratory distress syndrome, and, in most critical patients, with a "cytokine storm". IL-6 might play a key role in the cytokine storm and might be a potential target to treat severe and critical COVID-19. Tocilizumab is a recombinant humanized monoclonal antibody, directed against IL-6 receptor.
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol / Piccirillo, M.C., Ascierto, P., Atripaldi, L., Cascella, M., Costantini, M., Dolci, G., Facciolongo, N., Fraganza, F., Marata, A., Massari, M., Montesarchio, V., Mussini, C., Negri, E.A., Parrella, R., Popoli, P., Botti, G., Arenare, L., Chiodini, P., Gallo, C., Salvarani, C., et al.. - In: CONTEMPORARY CLINICAL TRIALS. - ISSN 1551-7144. - 98:(2020), pp. 106165-106165. [10.1016/j.cct.2020.106165]
TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol
Dolci, Giovanni;Mussini, Cristina;Salvarani, Carlo;Perrone, Francesco
2020
Abstract
Pneumonia is the most frequent complication of COVID-19, due to an aberrant host immune response that is associated with an acute respiratory distress syndrome, and, in most critical patients, with a "cytokine storm". IL-6 might play a key role in the cytokine storm and might be a potential target to treat severe and critical COVID-19. Tocilizumab is a recombinant humanized monoclonal antibody, directed against IL-6 receptor.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
